葡萄提取物(Entelon) - 在研适应症：骨关节炎，静脉功能不全_专利_临床

概要

基本信息

药物类型

中药

别名

Enteron、Vitis vinifera Seed Extract

靶点-

作用机制-

治疗领域

心血管疾病皮肤和肌肉骨骼疾病

在研适应症

骨关节炎静脉功能不全

非在研适应症

膝关节炎

原研机构

Hanlim Pharm Co., Ltd.

在研机构

Hanlim Pharm Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2011-01-01),

骨关节炎静脉功能不全

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

关联

4

项与葡萄提取物相关的临床试验

NCT05358080 / Recruiting临床4期

A Multi-center, Randomized, Double-blind, Placebo-controlled, Superiority, Phase IV Trial to Evaluate the Efficacy and Safety of Entelon 50mg Compared to Placebo in Patients With Non-Proliferative Diabetic Retinopathy

This clinical trial is a multi-center, double-blind, randomized, placebo controlled , parallel design, superiority, phase 4 study to evaluate the efficacy and safety of Entelon 50mg in 396 patients with non-proliferative diabetic retinopathy.

开始日期2022-05-27

申办/合作机构

Hanlim Pharm Co., Ltd.

NCT04882228 / Unknown status临床4期

A Multicenter, Double-blind, Randomized, Active Controlled, Parallel Group, Non-inferiority Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD)

This clinical trial is a multi-center, double-blind, randomized, active controlled , parallel design, non-inferiority phase 4 study to evaluate the efficacy and safety of Entelon 150mg in 278 patients with chronic venous disease.

开始日期2021-01-28

申办/合作机构

Hanlim Pharm Co., Ltd.

NCT03962296 / Completed临床4期IIT

A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy

This was a multicentre, randomised, double-blind controlled study that compared the efficacy and safety of V. vinifera extract, calcium dobesilate (CD), and placebo in subjects with DME. Patients made 6 clinic visits, namely the screening visit; baseline visit (T0); and follow-up visits at 3 (T3), 6 (T6), 9 (T9), and 12 (T12) months.

开始日期2012-11-21

申办/合作机构

Hanyang University

[+1]

100 项与葡萄提取物相关的临床结果

登录后查看更多信息

100 项与葡萄提取物相关的转化医学

登录后查看更多信息

100 项与葡萄提取物相关的专利（医药）

登录后查看更多信息

2

项与葡萄提取物相关的文献（医药）

2013-12-01·Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia4区 · 医学

Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNFα treatment.

4区 · 医学

Article

作者: Proietti, I ; La Viola, G ; Zuber, S ; Nicolucci, F ; Pampena, R ; Potenza, C ; Tolino, E ; Mancini, M T ; Bernardini, N ; Soccodato, V ; Skroza, N ; Balduzzi, V

AIM:

Psoriasis is a systemic inflammatory immune-mediated skin disease. Recently a relationship with metabolic syndrome in terms of psoriasis severity and response to therapy was observed.

METHODS:

We performed an open-label randomized controlled study to evaluate the role of a nutraceutical containing Q10 coenzyme, Krill-oil, lipoic acid, resveratrol, Vitis vinifera seed oil, vitamin E and selenium in addition to etanercept therapy for patients affected by psoriasis and metabolic syndrome. Forty patients were enrolled and divided into two arms, one receiving only etanercept, one other receiving also the neutraceutical. After a period of 3 months (T1) a second evaluation of the considered parameters was performed.

RESULTS:

At T1 statistically significant differences were detected in HDL cholesterol and triglycerides values both comparing the two arms and in the nutraceutical arm.

CONCLUSION:

Our results show that the dietary addiction of the nutraceutical to the etanercept therapy in patients affected by both psoriasis and metabolic syndrome could help to restore the normal lipid profile.

Molecules (Basel, Switzerland)3区 · 化学

Entelon® (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells

3区 · 化学

ArticleOA

作者: Lee, Jeong Eon ; Kim, Sung A ; Lo, Eunji ; Jeong, Yisun ; Yoon, Sun Young ; Kim, Seok Won ; Nam, Seok Jin ; Kim, Sangmin ; You, Daeun

Interleukin-1 (IL1) is a proinflammatory cytokine and promotes cancer cell proliferation and invasiveness in a diversity of cancers, such as breast and colon cancer. Here, we focused on the pharmacological effect of Entelon® (ETL) on the tumorigenesis of triple-negative breast cancer (TNBC) cells by IL1-alpha (IL1A). IL1A enhanced the cell growth and invasiveness of TNBC cells. We observed that abnormal IL1A induction is related with the poor prognosis of TNBC patients. IL1A also increased a variety of chemokines such as CCL2 and IL8. Interestingly, IL1A expression was reduced by the ETL treatment. Here, we found that ETL significantly decreased the MEK/ERK signaling pathway in TNBC cells. IL1A expression was reduced by UO126. Lastly, we studied the effect of ETL on the metastatic potential of TNBC cells. Our results showed that ETL significantly reduced the lung metastasis of TNBC cells. Our results showed that IL1A expression was regulated by the MEK/ERK- and PI3K/AKT-dependent pathway. Taken together, ETL inhibited the MEK/ERK and PI3K/AKT signaling pathway and suppressing the lung metastasis of TNBC cells through downregulation of IL1A. Therefore, we propose the possibility of ETL as an effective adjuvant for treating TNBC.

100 项与葡萄提取物相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V03A	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨关节炎	韩国	Hanlim Pharm Co., Ltd.	2011-01-01
静脉功能不全	韩国	Hanlim Pharm Co., Ltd.	2011-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床3期	-	Hanlim Pharm Co., Ltd.	2012-07-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01768520 (CTgov)	临床3期	膝关节炎	338	Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks+Enteron tab. 150mg (Entelon Tab. 150mg)	鏇憲繭鑰廠選齋艱糧衊(積淵衊夢衊簾糧構願獵) = 壓窪醖艱襯製膚廠構廠範願獵淵蓋鏇積鏇夢範 (觸襯衊鹽憲齋壓製鬱窪, 顧鑰齋襯夢顧鏇壓築鏇 ~ 築膚鹹壓淵餘壓醖蓋夢) 更多	-	2019-06-24
				Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks (Celebrex Cap.)	鏇憲繭鑰廠選齋艱糧衊(積淵衊夢衊簾糧構願獵) = 顧遞鑰艱觸鬱齋網觸襯範願獵淵蓋鏇積鏇夢範 (觸襯衊鹽憲齋壓製鬱窪, 鹹選鹽積構艱鹽鏇蓋製 ~ 製鹽廠選獵簾獵壓膚製) 更多